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DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY
Drug Therapy: Tenofovir
Patient Scenario
A 52-year-old woman who is in otherwise excellent
health is evaluated for liver test abnormalities. Her
aspartate aminotransferase and alanine aminotransfer-
ase levels are 130 U/L and 142 U/L, respectively, and
her alkaline phosphatase, bilirubin, albumin, and creat-
inine levels are normal. Her body mass index is 25.5
kg/m2, and physical examination is unremarkable.
Serological test results are as follows: hepatitis B sur-
face antigen–positive, immunoglobulin G hepatitis B
core antibody–positive, hepatitis B surface antibody–
negative, hepatitis B e antigen–negative, anti–hepatitis
B e antibody–positive, and a hepatitis B virus DNA
count of 2.4 million IU/mL. Test results for hepatitis
C, human immunodeficiency virus, and delta hepatitis
are negative. Although a liver biopsy was not per-
formed, there is no clinical, laboratory, or radio-
graphical evidence of cirrhosis. What is the role of
tenofovir in this patient?
The Problem: Antiviral Therapy for Hepatitis
B. When to Start? Which Drugs?
An increased number of efficacious and safe treat-
ment options has broadened the indications for the
treatment of hepatitis B. Treatment is clearly indicated
in patients with life-threatening liver disease (such as
acute liver failure, decompensated cirrhosis, or severe
flare of hepatitis) and in those with compensated cir-
rhosis and high levels of serum hepatitis B virus
(HBV) DNA. For patients with precirrhotic liver dis-
ease, the decision to start treatment is usually based on
biochemical or histological evidence of active or
advanced liver disease: elevated aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) or
moderate-severe inflammation (Metavir activity score
A2 or histological activity index 7) or fibrosis
(Metavir fibrosis score F2 or Ishak fibrosis score
3), in the presence of high levels of serum HBV
DNA. Because liver biopsies are not performed on all
patients in clinical practice, indications for hepatitis B
treatment have relied primarily on ALT and HBV
DNA levels.
Antiviral therapy is recommended for hepatitis B e
antigen (HBeAg)-positive patients who have ALT levels
that fluctuate or are persistently >2 times the upper
limit of normal and who remain HBeAg-positive after
3-6 months of observation (to determine if they might
undergo spontaneous HBeAg seroconversion).1-3 A
threshold serum HBV DNA level has not been
included in some guidelines because the vast majority
of HBeAg-positive patients have very high HBV DNA
levels (>9 log IU/mL). Antiviral therapy is also recom-
mended for patients with normal or slightly elevated
ALT levels if there is histological evidence of signifi-
cant liver disease, or if the patient remains HBeAg-
positive beyond the age of 40 years. Although large
population-based studies have shown that high serum
HBV DNA is associated with adverse outcomes, anti-
viral therapy is not recommended for young HBeAg-
positive patients with persistently normal ALT
(immune tolerance phase) because response rates are
lower in these patients,4,5 and it is possible that some
of them will undergo spontaneous HBeAg seroconver-
sion in the ensuing years.
Antiviral therapy is recommended for HBeAg-nega-
tive patients who have ALT levels that fluctuate or are
persistently >2 times the upper limit of normal and
have a serum HBV DNA count of >20,000 IU/mL.1-3
Lower ALT and HBV DNA cutoffs should be used in
older patients and in patients with histological evidence
of significant liver disease. Fluctuations in ALT and
HBV DNA are common in HBeAg-negative patients;
therefore, patients who have normal ALT and low or
undetectable HBV DNA at presentation should be
closely monitored for at least 12 months to determine if
they are in an inactive carrier state or if they have
HBeAg-negative hepatitis.
The key decision regarding choice of treatment is
whether to use interferon (IFN) or a nucleos(t)ide
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analog. The advantages of IFN include a finite dura-
tion of treatment, a higher rate of hepatitis B surface
antigen (HBsAg) loss, and lack of drug resistance
mutations. The disadvantages of IFN include need for
parenteral administration and frequent adverse effects.
It should be emphasized that although IFN is adminis-
tered for a finite duration, only 25%-35% of HBeAg-
positive patients have sustained HBeAg seroconver-
sion6 and 13%-18% of HBeAg-negative patients have
sustained viral suppression during posttreatment fol-
low-up of up to 3-5 years.7 Furthermore, a higher rate
of HBsAg loss is observed mainly in HBeAg-positive
patients with genotype A infection.6 The advantages of
nucleos(t)ide analogs include oral administration and
infrequent adverse effects. A major advantage of nucle-
os(t)ide analogs is that they can be administered safely
in patients with decompensated liver disease, although
a recent case report found that lactic acidosis can occur
in patients with severe liver failure.8 The main disad-
vantage of nucleos(t)ide analogs is the need for long
duration and often lifelong treatment to maintain viral
suppression. Unlike IFN, nucleos(t)ide analogs lack
immune modulatory activities and have no direct
effect on clearance of infected hepatocytes or cova-
lently closed circular DNA. This accounts for the high
rate of viral relapse when treatment is stopped.
Another disadvantage of nucleos(t)ide analogs is drug
resistance, although this problem has been greatly
diminished with the availability of newer drugs such as
entecavir and tenofovir, which have high genetic bar-
riers to resistance.
The choice of antiviral therapy should be made
jointly between the physician and the patient. Young
patients with precirrhotic liver disease who are reluc-
tant to commit to many years of treatment and have
no contraindications to IFN treatment should be
encouraged to try IFN, particularly if they are HBeAg-
positive with high ALT and low HBV DNA levels or
have genotype A infection.9 IFN should also be con-
sidered in young women who plan to start a family in
the next few years. Older patients, those with decom-
pensated liver disease, and those with contraindications
to IFN therapy should receive nucleos(t)ide analog
therapy. Of the five approved nucleos(t)ide analogs,
only entecavir and tenofovir meet the criteria for an
ideal first-line drug owing to their potent antiviral ac-
tivity, low risk of antiviral resistance, and good safety
profile.
The choice between entecavir and tenofovir depends
on patient characteristics and safety profile (Table 1).
Tenofovir is active against lamivudine-, telbivudine-,
and entecavir- resistant HBV, and is partially active
against adefovir-resistant HBV. Entecavir is active
against adefovir- and tenofovir- resistant HBV. It is
also active against lamivudine- and telbivudine- resist-
ant HBV, but a higher dose is required and the risk of
subsequent entecavir resistance is high (51% after 5
years).10 Tenofovir is a class B drug regarding safety in
pregnancy, and data on approximately 800 infants
born to women with human immunodeficiency virus
(HIV) and HBV coinfection did not reveal any
increased risk of birth defects.11 Entecavir, on the
other hand, is a class C drug, and safety data in
human pregnancies are limited. Tenofovir is associated
with a small risk of nephrotoxicity ranging from
decrease renal clearance to renal tubular defects,
including Fanconi anemia.12,13 Tenofovir has also been
reported to be associated with decreased bone mineral
density in patients with HIV and HBV coinfection.14
Entecavir in doses severalfold higher than that used in
humans was associated with higher rates of tumors in
the brain, lungs, and liver in rodents.15 To date, there
is no evidence that entecavir increases the risk of neo-
plasms in humans. Tenofovir may be administered
with or without food, whereas entecavir should be
administered on an empty stomach.
Although tenofovir and entecavir are both ideal
first-line drugs, tenofovir is preferred in patients who
have received lamivudine previously, in young women
Table 1. Comparison of Entecavir and Tenofovir
Entecavir Tenofovir
Antiviral activity




Entecavir-resistant HBV — Yes
Adefovir-resistant HBV Yes Decreased
activity
Tenofovir-resistant HBV Yes —
Virological response, week 48-52
HBeAgþ patients
Log decrease in HBV DNA 6.9 6.2
HBeAg seroconversion 21% 21%
HBsAg loss 2% 3%
HBeAg patients
Log decrease in HBV DNA 5.0 4.6
HBsAg loss <1% 0%
Genotypic resistance
Nucleoside-naı̈ve patients 1.2% (year 5) 0% (year 3)
Lamivudine-experienced patients 51% (year 5) Not available
Adverse effects None Nephrotoxicity,
decreased bone
mineral density
Safety in pregnancy Class C Class B
Dosage
Nucleoside-naı̈ve patients 0.5 mg/day 300 mg/day
Nucleos(t)ide-experienced patients 1.0 mg/day 300 mg/day
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who plan to start a family in the next few years, and
in patients who want more flexibility with regard to
the time of day at which they take their medicine;
entecavir is preferred in older patients and in patients
with other medical conditions that increase the risk of
renal failure.
Tenofovir
Tenofovir is administered as the prodrug tenofovir
disoproxil fumarate (9-[(R)-2-(phosphonomethoxy)-
prophy]adenin, or PMPA), a nucleotide that is phos-
phorylated to PMPApp. PMPApp works as a chain
terminator if incorporated into the DNA chain and is
a competitive inhibitor of natural deoxyadenosine 50-
triphosphate. After oral administration, tenofovir diso-
proxil fumarate is converted to tenofovir by plasma
esterases. Tenofovir is eliminated by a combination of
glomerular filtration and active tubular secretion.
A dose ranging study in HIV-1–infected patients
revealed that a 300-mg dose of tenofovir was optimal.
Dose ranging studies have not been performed in
patients with HBV infection. The dosage approved for
treatment of both nucleos(t)ide-naı̈ve and nucleos (t)ide-
experienced HBV patients is 300 mg/day. Dose adjust-
ments should be made in patients with renal impairment
to achieve optimal plasma exposure (Table 2); however,
data on the efficacy of these dose regimens in suppressing
HBV replication are not available.
In vitro studies have shown that tenofovir and ade-
fovir have similar antiviral activity on a molar basis.
This finding explains why tenofovir administered in
300-mg doses is more effective in suppressing HBV
replication than 10-mg doses of adefovir in clinical
practice. The mutations associated with primary resist-
ance to tenofovir have not been clearly defined. No
confirmed tenofovir resistance after up to 3 years of
treatment has been reported in phase III trials,16 but it
should be emphasized that the study design in these
trials allowed for the addition of emtricitabine at week
72 in patients who still had detectable serum HBV
DNA. Therefore, the rate of resistance during tenofo-
vir monotherapy beyond week 72 is unknown. An ala-
nine to threonine substitution at position 194
(rtA194T) has been reported to be associated with
tenofovir resistance.17 HBV variants with rtA194T
mutation remain susceptible to entecavir.18 In vitro
studies have found that susceptibility of HBV isolates
with adefovir resistance mutations, alanine to valine or
alanine substitution at position 181 (rtA181V/T) or
asparagine to threonine substitution at position 236
(rtN236T), to tenofovir is decreased by three- to four-
fold.19 Clinical studies have confirmed that tenofovir
is less effective in suppressing HBV replication in
patients with adefovir resistance than in nucleos(t)ide-
naı̈ve patients.20
Tenofovir is more efficacious than adefovir in
patients with lamivudine or telbivudine resistance.
Whereas ‘‘add-on’’ therapy was recommended when
adefovir was used as rescue therapy, preliminary data
suggest that ‘‘switch-to’’ therapy may suffice when
tenofovir is used as rescue therapy.20 Patients with sub-
optimal viral suppression during adefovir therapy and
no confirmed drug resistance will also benefit from
switching to tenofovir, but tenofovir is not an optimal
rescue therapy for those with confirmed adefovir resist-
ance. In vitro data suggest that tenofovir is effective in
the management of patients with entecavir resistance,
but clinical data are limited. It is unclear whether
tenofovir should be added to or substituted for enteca-
vir. For patients with prior lamivudine resistance and
subsequent entecavir resistance, it might be more
appropriate to add tenofovir.
Tenofovir is available as a monotherapeutic agent
(Viread) or in combination with emtricitabine (Tru-
vada). The combination pill makes it more convenient
for patients who require tenofovir plus a nucleoside, as
in the case of patients who have acquired resistance to
sequential monotherapy with lamivudine and then
adefovir.
Monitoring for Response and Drug-Related
Adverse Effects
Patients receiving tenofovir should be tested for se-
rum HBV DNA every 3 months to assess virological
response and to detect virological breakthrough. Fre-
quency of HBV DNA testing may be decreased to ev-
ery 6 months after serum HBV DNA has become
undetectable. Patients with virological breakthrough
should be counseled regarding the importance of med-
ication adherence. Confirmation of genotypic resist-
ance should be performed whenever possible before
treatment is modified. Because signature resistance
Table 2. Dose Adjustment of Tenofovir in Patients With
Altered Creatinine Clearance
Creatinine Clearance (mL/min) Recommended 300-mg Dosing Interval
50 Every 24 hours
30-49 Every 48 hours
10-29 Every 72-96 hours
<10 and not on dialysis Not available
Hemodialysis patients Every 7 days or after a total
of 12 hours of dialysis
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mutations have not been established, interpretation of
the sequencing result can be problematic when pre-
treatment sequences are not available for comparison
and in vitro susceptibility assays are not feasible.
In patients who were HBeAg-positive at the start of
treatment, HBeAg and HBe antibody should be tested
every 6 months to document HBeAg seroconversion.
In patients who were HBeAg-negative at the start of
treatment, HBsAg should be tested annually to docu-
ment HBsAg loss. Treatment may be discontinued in
HBeAg-positive patients who have confirmed HBeAg
seroconversion and who have completed 12 months of
consolidation therapy as well as in HBeAg-negative
patients who have confirmed HBsAg loss.
Serum chemistries including creatinine and phos-
phorus should be monitored every 6 months. Monitor-
ing may be more frequent in patients with impaired
baseline renal function or other medical conditions
that increase the risk of renal failure.
Areas of Uncertainty
Since the approval of tenofovir for the treatment of
hepatitis B in 2008, much has been learned about its
efficacy in various settings; however, there are still areas
of uncertainty. Would combination therapy of tenofo-
vir and IFN or a nucleoside be superior to tenofovir
monotherapy? Available data suggest that combination
therapy is unlikely to improve viral suppression or to
decrease drug resistance for nucleoside-naı̈ve patients.
It is also unclear whether addition of IFN will improve
immune control and increase the rate of HBsAg loss.
Case series suggest that tenofovir monotherapy may
suffice in patients with lamivudine-, telbivudine-, or
entecavir- resistance, but longer follow-up is needed to
determine the risk of subsequent tenofovir resistance.
Data from the Antiretroviral Registry suggest that
tenofovir is safe even when administered during the
first trimester of pregnancy, but it remains unclear
whether tenofovir increases the risk of miscarriage and
whether tenofovir in lactating mothers will have any
adverse effect on the growth and development of the
infant. Given the potential for nephrotoxicity, the
long-term safety of tenofovir needs to be clarified, par-
ticularly for transplant recipients receiving concomitant
calcineurin inhibitors. Furthermore, the recent report
of entecavir-associated lactic acidosis in patients with
severe liver failure may be a class effect, and further
study is needed to clarify the safety of tenofovir in
liver transplant recipients and in patients with acute
liver failure or decompensated cirrhosis.
Recommendations
The patient described in this scenario should be
started on antiviral treatment. It is likely that she has
been infected with HBV for more than five decades,
and her serum HBV DNA level is very high. Further-
more, her elevated AST and ALT levels indicate that
she has HBeAg-negative hepatitis. Because she is in
otherwise excellent health and has no evidence of cir-
rhosis, she is a candidate for pegylated IFN, entecavir,
or tenofovir. Any of these first-line therapies would be
appropriate depending on the patient’s preference. If
the patient opts for IFN, treatment will be adminis-
tered for 1 year. Recent data suggest that monitoring
serum HBsAg titer may be more accurate than moni-
toring serum HBV DNA in predicting long-term viral
suppression and may be considered if this test is avail-
able. If the patient chooses entecavir or tenofovir,
treatment will be administered until she becomes
HBsAg-negative, which will likely take many years if it
were to occur. Regardless of the choice of treatment,
this patient should be monitored for virological
response and adverse events, and HCC surveillance
should also be performed.
Note: Tenofovir is marketed in the United States as
Viread (Gilead Sciences). The combination of emtrici-
tabine (200 mg) and tenofovir (300 mg) is marketed
as Truvada (Gilead Sciences). Entacavir is marketed as
Baraclude (Bristol-Myers Squibb) and comes in 0.5
mg and 1 mg tablets. The costs for a 30-day supply
are: Viread (300 mg), US $853; Truvada, US $1,319;
and Baraclude (0.5 mg and 1 mg), US $941. The Bar-
aclude tablets are triangular in shape and are not
scored, making it difficult to split them without the
use of a pill cutter.
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